ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
0,00%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,98
-0,03%
Bitcoin
64 579,55
-0,37%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pacira BioSciences Inc (PCRX)

  7. Pacira BioSciences Inc (PCRX) Actualités

PCRX

Pacira BioSciences (PCRX)

Pacira BioSciences Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PCRX
DateHeureSourceTitreSymboleSociété
14/06/202400h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PCRXPacira BioSciences Inc
13/06/202423h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PCRXPacira BioSciences Inc
13/06/202416h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PCRXPacira BioSciences Inc
30/05/202414h00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
10/05/202413h00GlobeNewswire Inc.Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029NASDAQ:PCRXPacira BioSciences Inc
08/05/202422h05GlobeNewswire Inc.Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior NotesNASDAQ:PCRXPacira BioSciences Inc
07/05/202422h02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PCRXPacira BioSciences Inc
07/05/202422h00GlobeNewswire Inc.Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase programNASDAQ:PCRXPacira BioSciences Inc
07/05/202414h00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
30/04/202414h00GlobeNewswire Inc.Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024NASDAQ:PCRXPacira BioSciences Inc
02/04/202414h00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
13/03/202412h00GlobeNewswire Inc.Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the KneeNASDAQ:PCRXPacira BioSciences Inc
06/03/202414h00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
29/02/202421h33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PCRXPacira BioSciences Inc
29/02/202414h00GlobeNewswire Inc.Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:PCRXPacira BioSciences Inc
22/02/202414h00GlobeNewswire Inc.Pacira to Report 2023 Financial Results on Thursday February 29, 2024NASDAQ:PCRXPacira BioSciences Inc
15/02/202414h36GlobeNewswire Inc.Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After BunionectomyNASDAQ:PCRXPacira BioSciences Inc
07/02/202414h00GlobeNewswire Inc.Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.NASDAQ:PCRXPacira BioSciences Inc
01/02/202416h45PR Newswire (US)G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball TeamsNASDAQ:PCRXPacira BioSciences Inc
04/01/202423h18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PCRXPacira BioSciences Inc
04/01/202423h00GlobeNewswire Inc.Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 RevenuesNASDAQ:PCRXPacira BioSciences Inc
03/01/202414h00GlobeNewswire Inc.Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PCRXPacira BioSciences Inc
21/12/202313h30GlobeNewswire Inc.Pacira Appoints Frank D. Lee as Chief Executive OfficerNASDAQ:PCRXPacira BioSciences Inc
10/11/202313h30GlobeNewswire Inc.Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block IndicationsNASDAQ:PCRXPacira BioSciences Inc
07/11/202314h00GlobeNewswire Inc.Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in NovemberNASDAQ:PCRXPacira BioSciences Inc
02/11/202313h00GlobeNewswire Inc.Pacira BioSciences Reports Third Quarter 2023 Financial ResultsNASDAQ:PCRXPacira BioSciences Inc
26/10/202314h00GlobeNewswire Inc.Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023NASDAQ:PCRXPacira BioSciences Inc
12/10/202314h00GlobeNewswire Inc.American Society of Anesthesiologists Announces New Industry Supporter Pacira BioSciences, Inc.NASDAQ:PCRXPacira BioSciences Inc
10/10/202314h00GlobeNewswire Inc.Pacira BioSciences Appoints Four New Independent Directors to its Board of DirectorsNASDAQ:PCRXPacira BioSciences Inc
02/10/202314h00GlobeNewswire Inc.American Society of Anesthesiologists and Pacira BioSciences, Inc. Announce New Grant to Advance Education and Enhance Patient CareNASDAQ:PCRXPacira BioSciences Inc
 Showing the most relevant articles for your search:NASDAQ:PCRX

Dernières Valeurs Consultées

USOTC
SGPPY
Spar (PK)
EU
BE0002791722
City of Brussels 0.248% ...
BIT
P1ZTH3
NLBNPIT1ZTH3 20991231 38...
LSE
ECL2
Eclipse Vct
ASX
MGRKOA
BIT
P1MDS2
NLBNPIT1MDS2 20240621 28...
ASX
PTB
PTB
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés